Shilpa Medicare is currently trading at RS 329.00, rising by 5.70 points or 1.76% from its previous closing of RS 323.30 on the Bombay Stock Exchange (BSE).

The stock opened at RS 321.00 and touched an intraday high of RS 332.00 and a low of RS 315.60. A total of 6,330 shares have been traded so far.

The BSE Group ‘A’ stock with a face value of RS 1 hit a 52-week high of RS 501.60 on June 16, 2025, and a 52-week low of RS 260.00 on January 27, 2026. Over the past week, the stock recorded a high of RS 359.95 and a low of RS 315.60. The company’s current market capitalization stands at RS 6,394.55 crore.

Promoters hold a 40.13% stake in the company, while institutional and non-institutional investors hold 19.30% and 40.56%, respectively.

In a key development, Shilpa Medicare has entered into a long-term strategic development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland, for a novel therapy targeting autoimmune and alloimmune disorders. Under the agreement, the Shilpa group will provide comprehensive CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support. The collaboration spans early-stage development through commercialization, positioning Shilpa as a lifecycle partner for the program.

The autoimmune and immune-modulation segment is among the fastest-growing therapeutic categories globally, driven by rising disease prevalence and increasing demand for targeted immunotherapies. By securing this mandate at an early stage, Shilpa strengthens its presence in high-value, innovation-driven pipelines with scalable commercial potential.

This marks the third major international development and manufacturing contract secured by the company, highlighting growing demand from Western biotech firms for its integrated R&D capabilities and advanced GMP manufacturing infrastructure. While financial details remain undisclosed, the agreement includes milestone-linked expansion opportunities and may evolve into a multi-year commercial supply arrangement, subject to successful clinical and regulatory progress.

Shilpa Medicare manufactures and exports high-quality Active Pharmaceutical Ingredients (APIs), fine chemicals, intermediates, herbal products, and specialty chemical products using advanced technology and adhering strictly to international quality standards.